Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

5 of 5 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Early Phase 1
6(85.7%)
Phase 2
1(14.3%)
7Total
Early Phase 1(6)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT06137365Phase 2Not Yet Recruiting

Cannabis for Obesity Trial

Role: lead

NCT06312657Early Phase 1Terminated

Behavioral Effects of Drugs Inpatient 44 Neurobehavioral Mechanisms of Opioid Choice

Role: lead

NCT03958474Early Phase 1Completed

Neurobehavioral Mechanisms of Choice in Opioid Use Disorder

Role: lead

NCT04296006Early Phase 1Completed

Neurobehavioral Mechanisms of Cocaine Choice

Role: lead

NCT01511640Early Phase 1Completed

Behavioral Effects of Pregabalin and Cannabis

Role: lead

NCT01906346Early Phase 1Completed

Impact of a Non-Drug Choice on Cocaine Reinforcement

Role: lead

NCT02383043Early Phase 1Completed

Impact of Sustained Release d-Amphetamine on Choice Between Cocaine and a Non-Drug Reinforcer

Role: lead

All 7 trials loaded